Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific gets preliminary FTC okay

This article was originally published in The Gray Sheet

Executive Summary

Acquisition of ICD manufacturer Guidant moves closer to completion after Boston Scientific inked an agreement with Federal Trade Commission staff on April 5. The firm says the consent decree resolves all outstanding U.S. government antitrust issues but still requires final sign-off from FTC commissioners. On or around April 7, the firm will withdraw and re-file its antitrust notification with the agency, giving commissioners 30 days to review the details of the new agreement. Boston Scientific also is awaiting the completion of an antitrust review by the Eur-opean Commission, which will likely push final closing of the deal to mid-April (1"The Gray Sheet" April 3, 2006, p. 3)...

You may also be interested in...

Final Countdown For Blockbuster Boston Scientific Deal

European Commission (EC) antitrust regulators signed off, with some conditions, on Boston Scientific's acquisition of Guidant April 11, leaving U.S. clearance as the only remaining hurdle to closing the deal

Boston Scientific Acquisition Vote Follows Week Of Bad News For Guidant

Boston Scientific and Guidant shareholders approved the merger of their companies in separate votes March 31, leaving U.S. and European antitrust clearances as the only remaining hurdles to closing the deal

RECOVERY Coronavirus Study ‘Will Attract Global Players To UK’

A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts